CTOs on the Move

Forest Laboratories

www.frx.com

 
Forest Laboratories is a pharmaceutical company headquartered in New York City, US. The company's research and development spending has grown rapidly in recent years and as of 2007, approached almost a billion US dollars a year, which put it on the list of the top 100 global corporations in R&D spending. Forest Laboratories is also known for licensing European pharmaceuticals for sale in the United States.
  • Number of Employees: 1K-5K
  • Annual Revenue: > $1 Billion
  • www.frx.com
  • 909 3rd Ave
    New York, NY USA 10022
  • Phone: 212.421.7850

Executives

Name Title Contact Details

Similar Companies

Sebia

Sebia is the world’s leading provider of clinical protein electrophoresis equipment and reagents for various diseases screening and monitoring.

Antigen Laboratories Inc

Antigen Laboratories Inc is a Liberty, MO-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Windgap Medical

Windgap Medical is developing health care products that meet the demands of your lifestyle. Our first product will improve the quality of life for patients living with severe allergies.

AdviNOW Medical

Our AI & AR powered technology reduces medical practice overhead, accelerates patient throughput, improves efficiency, and speeds up data collection.

La Jolla Pharmaceutical Company

La Jolla Pharmaceutical Company is a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases. The Company has four product candidates in development. LJPC-501 is La Jolla’s proprietary formulation of angiotensin II for the potential treatment of catecholamine-resistant hypotension and hepatorenal syndrome. GCS-100 is La Jolla’s first-in-class galectin-3 inhibitor for the potential treatment of chronic kidney disease. LJPC-1010, La Jolla’s second-generation galectin-3 inhibitor, is a more potent and purified derivative of GCS-100 that can be delivered orally for the potential treatment of nonalcoholic steatohepatitis and other diseases characterized by tissue fibrosis. LJPC-401 is La Jolla’s novel formulation of hepcidin for the potential treatment of conditions characterized by iron overload, such as hemochromatosis and beta thalassemia